Werfen Launches Innovative ACL TOP Family 70 Series Hemostasis Testing Systems in North America

Werfen Introduces the Next Generation in Hemostasis Testing

A New Era for Hemostasis Testing Systems

On March 31, 2025, Werfen has officially introduced the ACL TOP Family 70 Series Hemostasis Testing Systems across North America. This significant advancement follows the necessary 510(k) clearance by the U.S. Food and Drug Administration and licensure by Health Canada, marking a new chapter in quality and innovation for hemostasis testing.

This latest series features several enhancements aimed at improving efficiency and connectivity within laboratory networks. Designed to meet the needs of modern testing environments, the ACL TOP Family 70 Series systems promise optimized workflows that are crucial for managing the increasing demands in hospital laboratories.

Streamlined Processes

Central to the improvements offered by the 70 Series is a shift towards automation and centralized management, especially in quality control (QC) and performance verification processes. When utilized with the HemoHub™ Intelligent Data Manager, these systems enable a unified application of a laboratory’s Quality Management System across multiple instruments and locations. This integration not only minimizes human error but also automates report generation and storage, ensuring comprehensive data management.

Furthermore, the performance verification process has been significantly streamlined, reducing a cumbersome five-step manual procedure to a simple two-step automated process. This enhancement translates into significant time savings for laboratory staff, thereby improving overall work quality and reducing operational costs.

Customer Feedback and Market Expectations

The enthusiasm surrounding the ACL TOP Family 70 Series has been palpable. Remo Tazzi, Vice President of Worldwide Marketing and Service at Werfen, stated, "The feedback from initial customers has been overwhelmingly positive, reinforcing the value the ACL TOP 70 Series systems deliver. We are eager to expand their placement across North America and globally, enhancing hemostasis testing capabilities for hospitals and patients worldwide."

A Versatile Portfolio for Diverse Testing Needs

The ACL TOP Family 70 Series boasts a versatile array of five models designed to address varying levels of testing demands—from low to high volume. The models range from the ACL TOP 370 tailored for low- to medium-volume labs, to the fully automated ACL TOP 770 models suitable for high-volume testing environments. All models share consistent performance quality, user-friendly software, and a comprehensive reagent portfolio, ensuring flexibility and scalability throughout the testing regimen.

Innovative Features to Ensure Quality

Among the standout features of the ACL TOP 70 Series is its automated pre-analytical checks—a groundbreaking innovation that first emerged in the previous ACL TOP Family 50 Series. This technology provides critical safeguards by detecting samples that fall outside assay-specific thresholds for factors such as Hemoglobin, Icterus, and Lipemia, as well as identifying underfilled samples and those with clots, thus guaranteeing high-quality test results.

A Complete Hemostasis Solution

The ACL TOP Family 70 Series forms part of a broader solution for hemostasis testing developed by Werfen. Alongside the advanced HemosIL® assays supplied for both routine and specialized testing needs, the organization also offers HemoCell® Specialized Lab Automation that enhances testing workflows. The holistic capabilities of the HemoHub Intelligent Data Manager promote comprehensive supervision of hemostasis laboratory networks.

Werfen, which has been a frontrunner in specialized diagnostics since 1966, is committed to maintaining excellence across its diverse clinical focus areas, such as hemostasis, acute care, and more. With its focus on innovation and quality service, Werfen is well positioned to lead in the evolving landscape of laboratory testing.

In conclusion, the ACL TOP Family 70 Series Hemostasis Testing Systems is a testament to Werfen's dedication to advancing laboratory testing processes. By prioritizing efficiency, accuracy, and security, Werfen continues to set standards in hemostasis diagnostics, ultimately benefiting healthcare providers and patients alike.